Gong M, Liu J, Sakurai R, Corre A, Anthony S, Rehan V K
Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, CA, USA.
Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, CA, USA.
Mol Genet Metab. 2015 Apr;114(4):604-12. doi: 10.1016/j.ymgme.2015.01.004. Epub 2015 Jan 29.
Due to the active inhibition of the adipogenic programming, the default destiny of the developing lung mesenchyme is to acquire a myogenic phenotype. We have previously shown that perinatal nicotine exposure, by down-regulating PPARγ expression, accentuates this property, culminating in myogenic pulmonary phenotype, though the underlying mechanisms remained incompletely understood. We hypothesized that nicotine-induced PPARγ down-regulation is mediated by PPARγ promoter methylation, controlled by DNA methyltransferase 1 (DNMT1) and methyl CpG binding protein 2 (MeCP2), two known key regulators of DNA methylation. Using cultured alveolar interstitial fibroblasts and an in vivo perinatal nicotine exposure rat model, we found that PPARγ promoter methylation is strongly correlated with inhibition of PPARγ expression in the presence of nicotine. Methylation inhibitor 5-aza-2'-deoxycytidine restored the nicotine-induced down-regulation of PPARγ expression and the activation of its downstream myogenic marker fibronectin. With nicotine exposure, a specific region of PPARγ promoter was significantly enriched with antibodies against chromatin repressive markers H3K9me3 and H3K27me3, dose-dependently. Similar data were observed with antibodies against DNA methylation regulatory factors DNMT1 and MeCP2. The knock down of DNMT1 and MeCP2 abolished nicotine-mediated increases in DNMT1 and MeCP2 protein levels, and PPARγ promoter methylation, restoring nicotine-induced down regulation of PPARγ and upregulation of the myogenic protein, fibronectin. The nicotine-induced alterations in DNA methylation modulators DNMT1 and MeCP2, PPARγ promoter methylation, and its down-stream targets, were also validated in perinatally nicotine exposed rat lung tissue. These data provide novel mechanistic insights into nicotine-induced epigenetic silencing of PPARγ that could be exploited to design novel targeted molecular interventions against the smoke exposed lung injury in general and perinatal nicotine exposure induced lung damage in particular.
由于脂肪生成程序的活性受到抑制,发育中的肺间充质的默认命运是获得肌源性表型。我们之前已经表明,围产期尼古丁暴露通过下调PPARγ表达,增强了这种特性,最终导致肌源性肺表型,尽管其潜在机制仍未完全了解。我们假设尼古丁诱导的PPARγ下调是由PPARγ启动子甲基化介导的,由DNA甲基转移酶1(DNMT1)和甲基CpG结合蛋白2(MeCP2)控制,这是两种已知的DNA甲基化关键调节因子。使用培养的肺泡间质成纤维细胞和围产期尼古丁暴露大鼠体内模型,我们发现PPARγ启动子甲基化与尼古丁存在时PPARγ表达的抑制密切相关。甲基化抑制剂5-氮杂-2'-脱氧胞苷恢复了尼古丁诱导的PPARγ表达下调及其下游肌源性标志物纤连蛋白的激活。随着尼古丁暴露,PPARγ启动子的一个特定区域显著富集了针对染色质抑制标志物H3K9me3和H3K27me3的抗体,呈剂量依赖性。用针对DNA甲基化调节因子DNMT1和MeCP2的抗体也观察到了类似的数据。敲低DNMT1和MeCP2消除了尼古丁介导的DNMT1和MeCP2蛋白水平的增加以及PPARγ启动子甲基化,恢复了尼古丁诱导的PPARγ下调和肌源性蛋白纤连蛋白的上调。在围产期尼古丁暴露的大鼠肺组织中也验证了尼古丁诱导的DNA甲基化调节剂DNMT1和MeCP2、PPARγ启动子甲基化及其下游靶点的改变。这些数据为尼古丁诱导的PPARγ表观遗传沉默提供了新的机制见解,可用于设计新的靶向分子干预措施,以对抗一般的烟雾暴露肺损伤,特别是围产期尼古丁暴露引起的肺损伤。